1. Home
  2. CRSP vs IFS Comparison

CRSP vs IFS Comparison

Compare CRSP & IFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • IFS
  • Stock Information
  • Founded
  • CRSP 2013
  • IFS 1897
  • Country
  • CRSP Switzerland
  • IFS Peru
  • Employees
  • CRSP N/A
  • IFS N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • IFS Commercial Banks
  • Sector
  • CRSP Health Care
  • IFS Finance
  • Exchange
  • CRSP Nasdaq
  • IFS Nasdaq
  • Market Cap
  • CRSP 4.9B
  • IFS 4.2B
  • IPO Year
  • CRSP 2016
  • IFS 2019
  • Fundamental
  • Price
  • CRSP $59.62
  • IFS $41.48
  • Analyst Decision
  • CRSP Buy
  • IFS Buy
  • Analyst Count
  • CRSP 16
  • IFS 1
  • Target Price
  • CRSP $72.27
  • IFS $30.00
  • AVG Volume (30 Days)
  • CRSP 1.8M
  • IFS 153.8K
  • Earning Date
  • CRSP 11-04-2025
  • IFS 11-11-2025
  • Dividend Yield
  • CRSP N/A
  • IFS 2.27%
  • EPS Growth
  • CRSP N/A
  • IFS 112.04
  • EPS
  • CRSP N/A
  • IFS 4.72
  • Revenue
  • CRSP $38,050,000.00
  • IFS $1,506,553,476.00
  • Revenue This Year
  • CRSP N/A
  • IFS N/A
  • Revenue Next Year
  • CRSP $348.18
  • IFS $10.80
  • P/E Ratio
  • CRSP N/A
  • IFS $8.67
  • Revenue Growth
  • CRSP N/A
  • IFS 34.92
  • 52 Week Low
  • CRSP $30.04
  • IFS $24.23
  • 52 Week High
  • CRSP $71.13
  • IFS $42.21
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 60.26
  • IFS 65.23
  • Support Level
  • CRSP $51.63
  • IFS $41.08
  • Resistance Level
  • CRSP $62.08
  • IFS $42.21
  • Average True Range (ATR)
  • CRSP 2.52
  • IFS 0.80
  • MACD
  • CRSP 0.84
  • IFS 0.00
  • Stochastic Oscillator
  • CRSP 78.13
  • IFS 77.15

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About IFS Intercorp Financial Services Inc.

Intercorp Financial Services Inc is a provider of banking, insurance, wealth management services and payments for retail customers and commercial clients in Peru. The company has four operating segments; the Banking segment includes Mainly loans, credit facilities, deposits, and current accounts, the Insurance segment provides life annuity products with single-premium payment and conventional life insurance products and other retail insurance products, the Wealth Management segment provides brokerage and investment management services. Its geographical segments include Peru and Panama.

Share on Social Networks: